Screen the A10 antibody for off-target binding to plasma membrane proteins and secreted proteins
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Cancer Institute (NCI), under the Department of Health and Human Services, has awarded a Firm Fixed-Priced purchase order to Charles River Discovery Research Services UK Limited. This award is for screening the A10 antibody for off-target binding to plasma membrane proteins and secreted proteins. The work will be performed in Saffron, United Kingdom.
Scope of Work
The awarded contract requires the contractor to perform an off-target screen on the NCI's A10 antibody. This antibody is designed to target cancer cells with high epidermal growth factor receptor expression. The screening aims to identify any problematic interactions with other cell surface proteins or secreted proteins that could lead to serious side effects if the antibody were administered to cancer patients. Although the A10 antibody is not known to bind other cell surface or secreted proteins, this screen is crucial to address potential unknown interactions.
Contract & Timeline
- Type: Firm Fixed-Priced Purchase Order
- Awardee: Charles River Discovery Research Services UK Limited
- Award Date: February 6, 2026
- Set-Aside: Not specified
- Place of Performance: Saffron, United Kingdom
Additional Notes
This award was the result of direct solicitation and negotiation by the NCI with Charles River Discovery Research Services UK Limited.